Jasper Therapeutics, Inc.

JSPR

US4718712023

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
20.4 ^USD	-3.68%		-5.51%	+158.56%

Apr. 03	Evercore ISI Initiates Jasper Therapeutics With Outperform Rating, Price Target is $65	MT
Mar. 28	Jasper Therapeutics Initiated at Outperform, Speculative Risk by RBC, Price Target Set at $70 Amid Bullish View on Lead Asset	MT

Jasper Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023

March 04, 2024 at 07:40 am EST

Jasper Therapeutics, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 64.47 million compared to USD 37.69 million a year ago. Basic loss per share from continuing operations was USD 6.18 compared to USD 10.33 a year ago.

Latest news about Jasper Therapeutics, Inc.

Evercore ISI Initiates Jasper Therapeutics With Outperform Rating, Price Target is $65	Apr. 03	MT
Jasper Therapeutics Initiated at Outperform, Speculative Risk by RBC, Price Target Set at $70 Amid Bullish View on Lead Asset	Mar. 28	MT
Jasper Therapeutics, Inc. Announces First Patient Dosed in Phase 1b/2a SPOTLIGHT Clinical Study of Briquilimab in Chronic Inducible Urticaria	Mar. 19	CI
TD Cowen Initiates Jasper Therapeutics With Outperform Rating	Mar. 18	MT
Jasper Therapeutics, Inc. Announces Additional Positive Phase 1b/2a Data on Briquilimab as A Conditioning Agent in the Treatment of Fanconi Anemia	Mar. 15	CI
Jasper Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 04	CI
Jasper Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 04	CI
Jasper Therapeutics Prices $50 Million Common Stock Offering -- Shares Rise	Feb. 06	MT
Jasper Therapeutics, Inc. Presents Positive Final Results from Phase 1 Study of Briquilimab in Patients with AML or MDS Undergoing Hematopoietic Cell Transplant in Oral Presentation At ASH 2023	Dec. 10	CI
Jasper Therapeutics Says First Patient Dosed in Phase 1b/2a Trial of Briquilimab for CSU Treatment	Nov. 30	MT
Jasper Therapeutics, Inc. Announces First Patient Dosed in Phase 1B/2A Clinical Study of Briquilimab in Chronic Spontaneous Urticaria	Nov. 30	CI
Jasper Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Jasper Therapeutics Announces Oral Presentation of Positive Final Results from Phase 1 Study of Briquilimab in Patients with AML or MDS Undergoing Hematopoietic Cell Transplant at ASH 2023	Nov. 02	CI
Jasper Therapeutics, Inc. Announces Board Changes	Nov. 01	CI
Transcript : Jasper Therapeutics, Inc. - Special Call	23-10-11
Jasper Therapeutics Appoints Herb Cross as CFO	23-09-25	MT
Jasper Therapeutics, Inc. Appointed Herb Cross, as Corporate Secretary	23-09-25	CI
Jasper Therapeutics, Inc. Announces Chief Financial Officer Changes	23-09-25	CI
Jasper Therapeutics, Inc.(NasdaqCM:JSPR) added to S&P Global BMI Index	23-09-18	CI
Jasper Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-11	CI
Capital One Initiates Jasper Therapeutics With Overweight Rating, $7 Price Target	23-08-11	MT
Jasper Therapeutics Strengthens Management Team with Key Appointments	23-08-03	CI
Jasper Therapeutics Reports First Patient Dosed in Phase 1 Trial of Briquilimab	23-06-22	MT
Jasper Therapeutics, Inc. Announces First Patient Dosed in A Phase 1 Trial of Briquilimab in Lower-Risk Myelodysplastic Syndrome	23-06-22	CI
Jasper Therapeutics, Inc. Appoints Scott Brun to Its Board of Directors	23-06-20	CI

Chart Jasper Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics targeting mast cell driven diseases, such as Chronic Spontaneous Urticaria (CSU) and Chronic Inducible Urticaria (CIndU). It also has ongoing programs in diseases where targeting diseased hemopoietic stem cells can provide benefits, such as Lower to Intermediate Risk Myelodysplastic Syndrome (LR-MDS), and stem cell transplant conditioning regimens. The Company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (c-Kit) receptor on mast and stem cells. The SCF/c-Kit pathway is a survival signal for mast cells. It is also developing briquilimab as a one-time conditioning therapy for severe combined immunodeficiency (SCID) patients undergoing a second stem cell transplant for which it is conducting a Phase 1/2 clinical trial.

Sector

Pharmaceuticals

Calendar

2024-05-09 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

20.4 USD

Average target price

64 USD

Spread / Average Target

+213.73%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
JASPER THERAPEUTICS, INC.	+158.56%	308M
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B

Other Pharmaceuticals